MN SF2985

Permits patients with terminal diseases to access investigational drugs, biological products, or devices that have completed phase 1 clinical trials but lack FDA approval.

Requires eligible patients to have exhausted all FDA-approved treatment options and obtain written informed consent and a physician's prescription or recommendation.

Manufacturers may voluntarily provide investigational treatments but are not required to do so, and may charge patients for manufacturing costs.

Prohibits health-related licensing boards from disciplining physicians who prescribe or recommend investigational treatments to eligible patients under this section.

Makes it a misdemeanor punishable by up to six months imprisonment and/or a $2,500 fine for state officials or employees to block eligible patients' access to investigational drugs, biological products, or devices.